Shifting the Spotlight: New Horizons in the Diagnosis and Management of Psoriatic Arthritis

Moderator(s)

• RH

  Rebecca Haberman, MD

  NYU Langone Health
  New York, New York, United States

  Disclosure(s): Johnson and Johnson: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Terminated)
• MH

  Mark Hwang, MD,MS

  UTHealth Houston
  Houston, TX, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

Session Coordinator(s)

• AA

  Anca Askanase, MD, MPH

  Director
  Columbia University Medical Center
  New York, New York, United States

  Disclosure(s): Alumis: Advisor or Review Panel Member (Ongoing); Amgen: Advisor or Review Panel Member (Terminated, August 15, 2024); AstraZeneca: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing); NKARTA: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Sanofi: Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing)
• MT

  Michael Toprover, MD

  New York University Langone Health
  New York, NY, United States

  Disclosure(s): Amgen: Consultant (Terminated, October 20, 2023); Scilex Holding: Advisor or Review Panel Member (Terminated, November 15, 2024)

Clinical practice guidelines are developed to help busy clinicians rapidly integrate evolving knowledge of therapeutic management into practice, but guidelines lag the accelerated pace of discovery. Diagnosis of early onset disease, particularly with risk factors, such as type and location of psoriasis, and the effects of the microbiome, play a role in recognizing and differentiating psoriatic arthritis from the differentials. There are many new treatment options in approved and in trials for PsA, and making the best choice can be challenging.

Presentations:

• 4:15 PM – 4:45 PM Central Time

  Approach to the Diagnosis and Risk Stratification of Early Onset Psoriatic Arthritis
  

  Speaker: Jose Scher, MD – New York University School of Medicine
• 4:45 PM – 5:15 PM Central Time

  Bridging the Guidelines: New and Up-and-Coming Therapeutic Options to Managing Psoriatic Arthritis